Filed by the Registrant ☒
|
| |
Filed by a Party other than the Registrant ☐
|
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☒
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material Pursuant to §240.14a-12
|
1.
|
To elect two class I directors to our board of directors, to serve until the 2024 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
|
2.
|
To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and
|
3.
|
To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
|
| |
By order of the Board of Directors,
|
|
| ||
|
| |
/s/Tryn T. Stimart
|
|
| |
Tryn T. Stimart
|
|
| |
Chief Legal Officer and Corporate Secretary
|
•
|
Online during the Annual Meeting. You may vote during the virtual Annual Meeting by following the instructions available at www.virtualshareholdermeeting.com/ABCL2021. If you hold your shares through a bank or broker and wish to vote at the virtual Annual Meeting, you must obtain a valid proxy from the firm that holds your shares. To join the annual meeting, you will need to have your 16-digit control number, which is included on your notice and your proxy card. In the event that you do not have a control number, please contact your broker, bank, or other nominee as soon as possible, so that you can be provided with a control number and gain access to the meeting.
|
•
|
By Internet or Telephone prior to the Annual Meeting. You can vote by proxy over the Internet or by telephone by following the instructions provided in the Notice. In order to be counted, proxies submitted by Internet or by telephone must be received by the cutoff time of 11:59 p.m. Eastern Time on June 14, 2021.
|
•
|
By Mail prior to the Annual Meeting. If you requested printed copies of the proxy materials by mail, you can vote by mailing your proxy as described in the proxy materials. Proxies submitted by mail must be received before the start of the Annual Meeting.
|
•
|
the class I directors are Véronique Lecault, Ph.D. and John Edward Hamer, Ph.D., and their terms will expire at the Annual Meeting;
|
•
|
the class II directors are Carl L. G. Hansen, Ph.D. and Michael Hayden, Ph.D., and their terms will expire at the annual meeting of shareholders to be held in 2022; and
|
•
|
the class III directors are John S. Montalbano CFA and Peter Thiel, and their terms will expire at the annual meeting of shareholders to be held in 2023.
|
Name
|
| |
Positions and Offices Held
|
| |
Director
Since
|
| |
Age
|
Véronique Lecault, Ph.D.
|
| |
Chief Operating Officer and Director
|
| |
2018
|
| |
36
|
John Edward Hamer, Ph.D.
|
| |
Director
|
| |
2018
|
| |
63
|
Name
|
| |
Positions and Offices Held
|
| |
Director
Since
|
| |
Class and Year
in Which Term
Will Expire
|
| |
Age
|
Carl L. G. Hansen, Ph.D.
|
| |
Chief Executive Officer and Director
|
| |
2012
|
| |
Class II—2022
|
| |
46
|
Michael Hayden, Ph.D.
|
| |
Director
|
| |
2019
|
| |
Class II—2022
|
| |
69
|
John S. Montalbano CFA
|
| |
Director
|
| |
2020
|
| |
Class III—2023
|
| |
56
|
Peter Thiel
|
| |
Director
|
| |
2020
|
| |
Class III—2023
|
| |
53
|
Name
|
| |
Position Held
|
| |
Officer
Since
|
| |
Age
|
Andrew Booth
|
| |
Chief Financial Officer
|
| |
2019
|
| |
47
|
|
| |
|
| |
|
| |
|
Tryn Stimart
|
| |
Chief Legal Officer,
Chief Compliance Officer
& Corporate Secretary
|
| |
2019
|
| |
51
|
|
| |
|
| |
|
| |
|
Ester Falconer, Ph.D.
|
| |
Chief Technology Officer
|
| |
2021
|
| |
46
|
|
| |
2019
|
| |
2020
|
Audit fees(1)
|
| |
$39,532
|
| |
$1,471,560
|
Tax fees(2)
|
| |
37,069
|
| |
119,942
|
Total fees(3)
|
| |
$76,601
|
| |
$1,591,502
|
(1)
|
Audit fees consist of fees for professional services provided by KPMG LLP for the audit of our annual financial statements, the review of interim consolidated financial statements and consultations on accounting matters directly related to the audit, and comfort letters, consents and assistance with and review of documents filed with the SEC.
|
(2)
|
Tax Fees consist of fees for professional services in connection with tax compliance, tax planning, and tax advice, including the review and preparation of our federal, state and foreign income tax returns and requests for rulings or technical advice from tax authorities.
|
(3)
|
Fees paid in Canadian dollars have been converted to U.S. dollars at the average exchange rate of $0.745 for the year ended December 31, 2020 and $0.754 for the year ended December 31, 2019, respectively, based on Bank of Canada average exchange rates.
|
•
|
The nominee shall have experience at a strategic or policymaking level in a business, government, non-profit or academic organization of high standing.
|
•
|
The nominee shall be highly accomplished in his or her respective field, with superior credentials and recognition.
|
•
|
The nominee shall be well regarded in the community and shall have a long-term reputation for the high ethical and moral standards.
|
•
|
The nominee shall have sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards of directors on which such nominee may serve.
|
•
|
To the extent such nominee serves or has previously served on other boards, the nominee shall have a demonstrated history of actively contributing at board meetings.
|
•
|
appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;
|
•
|
pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;
|
•
|
reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;
|
•
|
reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;
|
•
|
coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
|
•
|
establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
|
•
|
recommending based upon the audit committee’s review and discussions with management and our independent registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form 10-K;
|
•
|
monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;
|
•
|
preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
|
•
|
reviewing material related person transactions for potential conflict of interest situations and approving such transactions; and
|
•
|
reviewing quarterly earnings releases.
|
•
|
annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer;
|
•
|
evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such evaluation (i) reviewing and determining the cash compensation of our Chief Executive Officer and (ii) reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans;
|
•
|
reviewing and approving the compensation of our other executive officers;
|
•
|
reviewing and establishing our overall management compensation, philosophy and policy;
|
•
|
overseeing and administering our compensation and similar plans;
|
•
|
evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq Listing Rules;
|
•
|
reviewing and approving our policies and procedures for the grant of equity-based awards;
|
•
|
reviewing and recommending to the board of directors the compensation of our directors;
|
•
|
preparing our compensation committee report if and when required by SEC rules;
|
•
|
reviewing and discussing annually with management our “Compensation Discussion and Analysis,” if and when required, to be included in our annual proxy statement; and
|
•
|
reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters.
|
•
|
developing and recommending to the board of directors criteria for board and committee membership;
|
•
|
establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by shareholders;
|
•
|
reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;
|
•
|
identifying individuals qualified to become members of the board of directors;
|
•
|
recommending to the board of directors the persons to be nominated for election as directors and to each of the board’s committees;
|
•
|
developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate governance guidelines; and
|
•
|
overseeing the evaluation of our board of directors.
|
Annual Retainer for Board Membership
|
| |
|
Annual service on the board of directors
|
| |
$40,000
|
Additional retainer for annual service as non-executive chairperson or lead director of the board of directors
|
| |
$30,000
|
Additional Annual Retainer for Committee Membership
|
| |
|
Annual service as audit committee chairperson
|
| |
$20,000
|
Annual service as member of the audit committee (other than chair)
|
| |
$10,000
|
Annual service as compensation committee chairperson
|
| |
$15,000
|
Annual service as member of the compensation committee (other than chair)
|
| |
$7,500
|
Annual service as nominating and corporate governance committee chairperson
|
| |
$10,000
|
Annual service as member of the nominating and corporate governance committee (other than chair)
|
| |
$5,000
|
Name(1)
|
| |
Fees Earned or
Paid in Cash
($)
|
| |
Option Award
($)(3)
|
| |
All Other
Compensation
($)
|
| |
Total
($)(4)
|
Michael Hayden, Ph. D.(3)
|
| |
41,793
|
| |
475,338(2)
|
| |
—
|
| |
517,131
|
John S. Montalbano CFA(3)
|
| |
6,087
|
| |
2,376,689
|
| |
—
|
| |
2,382,776
|
(1)
|
As of December 31, 2020, Dr. Hamer and Mr. Thiel did not hold any outstanding equity awards.
|
(2)
|
Genworks 2 has been granted stock options for Dr. Hayden’s service on our board of directors. As of December 31, 2020, Genworks 2 held options to purchase 540,000 common shares.
|
(3)
|
The amounts reported represent the aggregate grant date fair value of the stock options granted to our directors during the 2020 fiscal year, calculated in accordance with ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 11 of our Consolidated Financial Statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying common shares.
|
(4)
|
The USD amount is based on a weighted-average exchange ratio of CAD $1.3422: USD $1.00 for 2020 as set forth on Bloomberg.
|
•
|
Carl L.G. Hansen, Ph.D., our Chief Executive Officer;
|
•
|
Véronique Lecault, Ph D., our Chief Operating Officer; and
|
•
|
Tryn T. Stimart, our Chief Legal Officer, Chief Compliance Officer & Corporate Secretary.
|
Name and Principal
Position
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus ($)
|
| |
Stock
Awards
($)
|
| |
Option
Awards
($)(1)
|
| |
Non-equity
Incentive Plan
Compensation
($)
|
| |
All Other
Compensation
($)
|
| |
Total ($)
|
Carl L.G. Hansen, Ph.D.
Chief Executive Officer
|
| |
2020
|
| |
296,155
|
| |
128,520
|
| |
—
|
| |
16,537,933
|
| |
—
|
| |
—
|
| |
16,962,608
|
|
2019
|
| |
177,381
|
| |
72,517
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
249,898
|
||
Véronique Lecault, Ph D.
Chief Operating Officer(2)
|
| |
2020
|
| |
196,533
|
| |
71,003
|
| |
—
|
| |
5,683,003
|
| |
—
|
| |
—
|
| |
5,950,539
|
Tryn T. Stimart
Chief Legal Officer,
Chief Compliance Officer & Corporate Secretary
|
| |
2020
|
| |
337,235
|
| |
298,400(3)
|
| |
—
|
| |
3,798,708
|
| |
—
|
| |
—
|
| |
4,434,343
|
|
2019
|
| |
115,152
|
| |
17,500
|
| |
—
|
| |
519,218
|
| |
—
|
| |
—
|
| |
651,869
|
(1)
|
The amounts reported represent the aggregate grant date fair value of the stock options granted to our named executive officers during the 2020 and 2019 fiscal years, as applicable, calculated in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 11 of our Consolidated Financial Statements included in our annual report on Form 10-K for the year ended December 31, 2020. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our named executive officers upon the exercise of the stock options or any sale of the underlying common shares.
|
(2)
|
Dr. Lecault was not a named executive officer for 2019.
|
(3)
|
This amount also includes a $200,000 discretionary bonus.
|
|
| |
|
| |
|
| |
Option Awards(1)
|
||||||||||||
Name
|
| |
Grant Date
|
| |
Vesting
Commencement
Date
|
| |
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
| |
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
| |
Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
|
| |
Option
Exercise
Price
|
| |
Option
Expiration
Date
|
Carl L.G. Hansen, Ph.D.
|
| |
12/10/2020(1)(6)
|
| |
12/10/2020
|
| |
—
|
| |
496,000
|
| |
—
|
| |
$20.00
|
| |
12/10/2030
|
|
| |
11/18/2020(2)(3)
|
| |
11/18/2020
|
| |
—
|
| |
898,000
|
| |
—
|
| |
$2.62
|
| |
11/18/2030
|
|
| |
10/29/2020(2)(3)
|
| |
10/29/2020
|
| |
—
|
| |
3,823,310
|
| |
—
|
| |
$2.29
|
| |
10/29/2030
|
Véronique Lecault, Ph.D.
|
| |
12/10/2020(1)(6)
|
| |
12/10/2020
|
| |
—
|
| |
190,800
|
| |
—
|
| |
$20.00
|
| |
12/10/2030
|
|
| |
10/29/2020(2)(3)
|
| |
10/29/2020
|
| |
—
|
| |
2,000,000
|
| |
—
|
| |
$2.29
|
| |
10/29/2030
|
|
| |
3/23/2017 (7)(4)
|
| |
11/8/2016
|
| |
333,333
|
| |
666,667
|
| |
—
|
| |
$0.19
|
| |
3/23/2027
|
Tryn Stimart
|
| |
12/10/2020(1)(6)
|
| |
12/10/2020
|
| |
—
|
| |
190,800
|
| |
—
|
| |
$20.00
|
| |
12/10/2030
|
|
| |
10/29/2020(2)(3)
|
| |
10/29/2020
|
| |
—
|
| |
850,000
|
| |
—
|
| |
$2.30
|
| |
10/29/2030
|
|
| |
10/30/2019(2)(5)
|
| |
8/22/2019
|
| |
625,000
|
| |
1,375,000
|
| |
—
|
| |
$0.32
|
| |
8/22/2029
|
(1)
|
The stock option award was granted under our 2020 Plan (as defined below). The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
|
(2)
|
The stock option award was granted under our Pre-IPO Plan (as defined below). The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
|
(3)
|
One-fourth of the shares subject to the stock option vests on the one year anniversary of the vesting commencement date and the remaining vests in equal quarterly installments for the next three years, subject to the named executive officer’s continuous service relationship with us through each such date. The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
|
(4)
|
For awards granted in 2020 with a per share exercise price denominated in CAD on 12/31/2020, the per share exercise price has been converted from CAD to USD based on a weighted-average exchange ratio of CAD $1.3422: USD $1.00 for 2020 as set forth on Bloomberg. Per share exercise price for awards granted prior to 2020 have been converted from CAD to USD based on the grant date exchange ratio of CAD $1.3152:USD $1.00 for October 30, 2019 and CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg.
|
(5)
|
One-fourth of the shares subject to the stock option vests on the one year anniversary of the vesting commencement date and the remaining vests in equal quarterly installments for the next three years, subject to the named executive officer’s continuous service relationship with us through each such date. Additionally, upon a “Change in Control” (as defined in the stock option agreement), the stock option shall immediately vest in full and be fully exercisable.
|
(6)
|
One-fourth of the shares subject to the stock option vests on December 31, 2021 and the remaining vests in equal quarterly installments for the next three years, subject to the named executive officer’s continuous service relationship with us through each such date. The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
|
(7)
|
These options vest annually over a six year period.
|
Plan Category
|
| |
Number of Shares of Common Stock to be
Issued Upon Exercise of Outstanding
Options
|
| |
Weighted-Average Exercise Price of
Outstanding Options
|
| |
Number of Shares of Common Stock
Remaining Available for Future Issuance
Under Equity Compensation Plans
(Excluding Securities Reflected in The First
Column)
|
Equity compensation plans approved by security holders(1)
|
| |
54,465,650
|
| |
1.19
|
| |
20,539,160
|
Equity compensation plans not approved by security holders
|
| |
—
|
| |
—
|
| |
—
|
Total
|
| |
54,465,650
|
| |
1.19
|
| |
20,539,160
|
(1)
|
As of March 31, 2021, there were 20,075,196 shares available for grant under the 2020 Plan, no shares available for grant under the 2015 Plan, and 1,119,160 shares available for grant under the ESPP.
|
•
|
the amount involved in the transaction exceeds, or will exceed $120,000; and
|
•
|
in which any of our executive officers, directors or holders of 5% or more of any class of our share capital, or the immediate family members of, or any person sharing the household with, the foregoing persons, or any affiliated entities, had or will have a direct or indirect material interest.
|
Purchaser
|
| |
Series A2 Convertible
Preferred
Shares Purchased
|
| |
Aggregate Purchase
Price
($)
|
DCVC Bio, L.P.(1)
|
| |
802,371
|
| |
10,000,030
|
Viking Global Opportunities Illiquid Investments Sub-Master LP(2)
|
| |
1,604,771
|
| |
20,000,061
|
Entities affiliated with Thiel Capital(3)
|
| |
758,479
|
| |
9,453,000
|
Total
|
| |
3,165,621
|
| |
39,453,091
|
(1)
|
John Edward Hamer, Ph.D., a member of our board of directors, is a Managing Partner at DCVC Bio, L.P., an entity that holds 5% or more of our common shares.
|
(2)
|
Viking Global Opportunities Illiquid Investments Sub-Master LP is a holder of 5% or more of our common shares.
|
(3)
|
ABE Investments LLC, The Founders Fund VII Principals Fund, LP, or FF-VIIP, The Founders Fund VII, LP, or FF-VII, and The Founders Fund VII Entrepreneurs Fund, LP, or FF-VIIE, together holds 5% or more of our common shares.
|
Purchaser
|
| |
Aggregate Principal
Amount of the
Convertible Notes
($)
|
DCVC Bio, L.P.(1)
|
| |
500,000
|
DRAGSA 76 LLC (2)
|
| |
6,150,000
|
Genworks 2 Consulting Inc.(3)
|
| |
2,000,000
|
Entities affiliated with Thiel Capital(4)
|
| |
35,430,000
|
Total
|
| |
44,080,000
|
(1)
|
John Edward Hamer, Ph.D., a member of our board of directors, is a Managing Partner at DCVC Bio, L.P, which is a holder of 5% or more of our common shares.
|
(2)
|
DRAGSA 76 LLC is an affiliate of Viking Global Opportunities Illiquid Investments Sub-Master LP, which is a holder of 5% or more of our common shares.
|
(3)
|
Reflects purchase by Genworks 2 Consulting Inc., or Genworks 2. The spouse of Michael Hayden, Ph.D., a member of our board of directors, has sole voting and investment power with respect to the shares held by Genworks 2.
|
(4)
|
Reflects purchases by ABE Investments LLC, The Founders Fund Growth, LP, or FFG, and The Founders Fund Growth Principals Fund, LP, or FFGP. ABE Investments LLC, FFG and FFGP were issued an aggregate of 800,000 common shares in connection with the completion of our initial public offering. ABE Investments LLC and certain other Founders Fund entities together hold 5% or more of our common shares, as described in more detail above.
|
•
|
each person we know to be the beneficial owner of 5% or more of our outstanding share capital;
|
•
|
each of our directors and director nominees;
|
•
|
each of our named executive officers; and
|
•
|
all of our current executive officers and directors as a group.
|
Name and address of beneficial owner
|
| |
Number of shares
beneficially
owned
|
| |
Percentage of
shares beneficially
owned
|
5% or Greater Shareholders:
|
| |
|
| |
|
Thermopylae Holdings Ltd.(1)
|
| |
61,202,750
|
| |
22.6%
|
DCVC Bio, L.P.(2)
|
| |
29,105,761
|
| |
10.7%
|
Entities affiliated with Viking Global Investors LP(3)
|
| |
19,283,744
|
| |
7.1%
|
Entities affiliated with Thiel Capital(4)
|
| |
14,360,427
|
| |
5.3%
|
|
| |
|
| |
|
Named Executive Officers and Directors:
|
| |
|
| |
|
Carl L.G. Hansen, Ph.D.(5)
|
| |
61,827,830
|
| |
22.8%
|
Tryn T. Stimart(6)
|
| |
1,600,500
|
| |
*
|
Véronique Lecault, Ph.D.(7)
|
| |
9,829,551
|
| |
3.6%
|
John Edward Hamer, Ph.D.(2)
|
| |
29,105,761
|
| |
10.7%
|
Michael Hayden, Ph.D. (8)
|
| |
1,221,642
|
| |
*
|
John S. Montalbano CFA(9)
|
| |
25,000
|
| |
*
|
Peter Thiel(4)
|
| |
14,360,427
|
| |
5.3%
|
All directors and executive officers as a group (9 persons)(10)
|
| |
124,115,795
|
| |
45.8%
|
*
|
Represents beneficial ownership of less than one percent.
|
(1)
|
Consists of 61,202,750 common shares held by Thermopylae Holdings Ltd. or Thermopylae, which is an entity wholly owned by Dr. Hansen.
|
(2)
|
Based solely on the Schedule 13G filed with the SEC on February 9, 2021 by (i) DCVC Bio, L.P., a Delaware limited partnership, or DCVC Bio, (ii) DCVC Bio GP, LLC, a Delaware limited liability company, or DCVC Bio GP, (iii) JNK Capital Management, LLC, a Delaware limited liability company, or JNK, (iv) ZNM Capital Management, LLC, a Delaware limited liability company, or ZNM, (v) Zachary Bogue, (vi) Matthew Ocko, (vii) John Edward Hamer, a member of our board of directors, and (viii) Kiersten Stead. Consists of 29,105,761 common shares held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. ZNM is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. JNK is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Messrs. Bogue and Ocko are managing members of ZNM and may be deemed to have indirect beneficial ownership of shares of
|
(3)
|
Based solely on the Schedule 13G/A filed with the SEC on February 16, 2021 by (i) Viking Global Investors LP, or VGI, (ii) Viking Global Opportunities GP LLC, or Opportunities GP, (iii) Viking Global Opportunities Portfolio GP LLC, or Opportunities Portfolio GP, (iv) Viking Global Opportunities Liquid Portfolio Sub-Master LP, or VGOL, (v) Viking Global Opportunities Illiquid Investments Sub-Master LP, or VGOP, (vi) DRAGSA 76 LLC, or DRAGSA 76, (vii) O. Andreas Halvorsen, (viii) David C. Ott and (ix) Rose S. Shabet. Consists of (i) 18,721,980 common shares held by VGOP, (ii) 361,764 common shares held by DRAGSA 76, and (iii) 200,000 common shares held by VGOL. Each of VGOP and VGOL has the authority to dispose of and vote the shares of common shares directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. DRAGSA 76 has the authority to dispose of and vote the shares of common shares directly owned by it, which power may be exercised by Viking Global Opportunities GP LLC, or Opportunities GP, and by VGI, an affiliate of Opportunities GP, which provides managerial services to DRAGSA 76. The membership interests of DRAGSA 76 are held by Viking Global Opportunities LP and Viking Global Opportunities Intermediate LP. Opportunities GP is the general partner of Viking Global Opportunities LP and Viking Global Opportunities Intermediate LP. Messrs. Halvorsen and Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC, general partner of VGI and Opportunities GP have shared authority to dispose of and vote the shares of common shares beneficially owned by VGI and Opportunities GP. The address of VGI, Opportunities GP, Opportunities Portfolio GP, VGOL, VGOP, DRAGSA 76, Mr. Halvorsen, Mr. Ott and Ms. Shabet is 55 Railroad Avenue, Greenwich, Connecticut 06830.
|
(4)
|
Based solely on the Schedule 13D filed with the SEC on December 28, 2020 by (i) Peter Thiel, a member of our board of directors, (ii) ABE Investments LLC, a Delaware limited liability company, (iii) The Founders Fund VII, LP, a Delaware limited partnership, or FF-VII, (iv) The Founders Fund VII Entrepreneurs Fund, LP, a Delaware limited partnership, or FF-VIIE, (v) The Founders Fund VII Principals Fund, LP, a Delaware limited partnership, or FF-VIIP and, together with FF-VII and FF-VIIE, the FF-VII Funds, (vi) The Founders Fund VII Management, LLC, a Delaware limited liability company, or FF-VIIM and, collectively with the FF-VII Funds, the FF-VII Persons, (vii) The Founders Fund Growth, LP, a Delaware limited partnership, or FFG, (viii) The Founders Fund Growth Principals Fund, LP, a Delaware limited partnership, or FFGP and, together with FFG, the FFG Funds, and (ix) The Founders Fund Growth Management, LLC, a Delaware limited liability company, or FFGM and, collectively with the FFG Funds, the FFG Persons. Consists of (i) 10,179,880 common shares held by ABE Investments LLC, (ii) 3,343,240 common shares held by FF-VII, (iii) 401,050 common shares held by FF-VIIP, (iv) 29,240 common shares held by FF-VIIE, (v) 382,357 common shares held by FFG, and (vi) 24,660 common shares held by FFGP. Mr. Thiel is the beneficial owner of ABE Investments LLC and has sole voting and dispositive power over the common shares held by ABE Investments LLC. Investment and voting decisions with respect to the common shares held by each of the FF-VII Funds are made by a committee comprised of the managing members of FF-VIIM, which is the general partner of each of the FF-VII Funds. The managing members of FF-VIIM are Mr. Thiel, Brian Singerman and Keith Rabois. As a result, each of FF-VIIM and Messrs. Thiel, Singerman and Rabois may be deemed to share voting and dispositive power with respect to the common shares held by the FF-VII Funds. Each of FF-VIIM and Messrs. Thiel, Singerman and Rabois disclaims beneficial ownership of the common shares held by the FF-VII Funds except to the extent of his or its respective pecuniary interest therein. Investment and voting decisions with respect to the common shares held by each of the FFG Funds are made by a committee comprised of the managing members of FFGM, which is the general partner of each of the FFG Funds. The managing members of FFGM are Messrs. Thiel, Singerman and Rabois. As a result, each of FFGM and Messrs. Thiel, Singerman and Rabois may be deemed to share voting and dispositive power with respect to the common shares held by the FFG Funds. Each of FFGM and Messrs. Thiel, Singerman and Rabois disclaims beneficial ownership of the common shares held by the FFG Funds except to the extent of his or its respective pecuniary interest therein. The principal business address of Mr. Thiel is c/o Thiel Capital LLC, 9200 Sunset Boulevard, Suite 1110, West Hollywood, California 90069. The principal business address of ABE Investments LLC is 1209 Orange Street, Wilmington, Delaware 19801. The principal business address of each of the FF-VII Persons, the FFG Persons and Messrs. Singerman and Rabois is c/o Founders Fund LLC, One Letterman Drive, Building D, 5th Floor, San Francisco, California 94129.
|
(5)
|
Consists of (i) the shares listed in footnote (1) and (ii) 625,080 common shares held by Hankla Family Trust, of which Dr. Hansen and his spouse are joint trustees.
|
(6)
|
Consists of (i) 250 common shares held by Mr. Stimart, (ii) 250 shares held by Mr. Stimart’s spouse, and (iii) 1,600,000 common shares underlying options exercisable within 60 days of April 1, 2021.
|
(7)
|
Consists of (i) 7,155,008 common shares held by Pacific Swell Capital Corp., or Pacific Swell, (ii) 1,273,630 common shares held by Slomo Family Trust, of which Dr. Lecault is a co-trustee, (iii) 61,580 common shares held by the spouse of Dr. Lecault, (iv) 1,006,000 common shares held by Dr. Lecault, and (v) 333,333 common shares underlying options exercisable within 60 days of April 1, 2021. Dr. Lecault is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The principal business address of Pacific Swell is 1300-777 Dunsmuir Street, PO Box 10444, Vancouver, BC V7Y 1K2, Canada.
|
(8)
|
Consists of (i) 1,103,397 common shares held by Genworks 2 Consulting, Inc., or Genworks 2, and (ii) 118,245 shares held by Dr. Hayden’s spouse. Dr. Hayden’s spouse has sole voting and investment power with respect to the shares held by Genworks 2. The principal business address Genworks 2 is 4484 West 7th Avenue, Vancouver, BC, Canada V6R1W9.
|
(9)
|
Consists of (i) 20,000 common shares held by Mr. Montalbano, and (ii) 5,000 common shares held by Mr. Montalbano’s spouse.
|
(10)
|
Consists of (i) 117,154,337 common shares held directly or indirectly and (ii) 6,961,458 common shares issuable upon exercise of options exercisable within 60 days of April 1, 2021.
|
|
| |
THE AUDIT COMMITTEE OF THE
BOARD OF DIRECTORS OF ABCELLERA
BIOLOGICS INC.
|
|
| |
|
|
| |
John S. Montalbano CFA, Chair
John Edward Hamer, Ph.D.
Michael Hayden, Ph.D.
|